|
Gene: MAP4K3 |
Gene summary for MAP4K3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MAP4K3 | Gene ID | 8491 |
Gene name | mitogen-activated protein kinase kinase kinase kinase 3 | |
Gene Alias | GLK | |
Cytomap | 2p22.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | B3KMM5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8491 | MAP4K3 | LZE24T | Human | Esophagus | ESCC | 1.29e-08 | 2.48e-01 | 0.0596 |
8491 | MAP4K3 | P1T-E | Human | Esophagus | ESCC | 2.87e-02 | 1.15e-01 | 0.0875 |
8491 | MAP4K3 | P2T-E | Human | Esophagus | ESCC | 8.77e-20 | 3.31e-01 | 0.1177 |
8491 | MAP4K3 | P4T-E | Human | Esophagus | ESCC | 3.89e-15 | 2.65e-01 | 0.1323 |
8491 | MAP4K3 | P5T-E | Human | Esophagus | ESCC | 8.72e-14 | 1.65e-01 | 0.1327 |
8491 | MAP4K3 | P8T-E | Human | Esophagus | ESCC | 2.27e-14 | 2.44e-01 | 0.0889 |
8491 | MAP4K3 | P9T-E | Human | Esophagus | ESCC | 4.95e-05 | 9.35e-02 | 0.1131 |
8491 | MAP4K3 | P10T-E | Human | Esophagus | ESCC | 3.54e-17 | 1.87e-01 | 0.116 |
8491 | MAP4K3 | P11T-E | Human | Esophagus | ESCC | 9.09e-03 | 2.11e-01 | 0.1426 |
8491 | MAP4K3 | P12T-E | Human | Esophagus | ESCC | 9.97e-17 | 3.47e-01 | 0.1122 |
8491 | MAP4K3 | P15T-E | Human | Esophagus | ESCC | 6.53e-09 | 2.97e-01 | 0.1149 |
8491 | MAP4K3 | P16T-E | Human | Esophagus | ESCC | 1.11e-06 | 9.74e-02 | 0.1153 |
8491 | MAP4K3 | P20T-E | Human | Esophagus | ESCC | 3.54e-07 | 7.11e-02 | 0.1124 |
8491 | MAP4K3 | P21T-E | Human | Esophagus | ESCC | 3.14e-09 | 9.21e-02 | 0.1617 |
8491 | MAP4K3 | P22T-E | Human | Esophagus | ESCC | 1.36e-11 | 1.88e-01 | 0.1236 |
8491 | MAP4K3 | P23T-E | Human | Esophagus | ESCC | 5.55e-07 | 1.87e-01 | 0.108 |
8491 | MAP4K3 | P24T-E | Human | Esophagus | ESCC | 1.86e-08 | 5.38e-02 | 0.1287 |
8491 | MAP4K3 | P26T-E | Human | Esophagus | ESCC | 3.01e-20 | 3.34e-01 | 0.1276 |
8491 | MAP4K3 | P27T-E | Human | Esophagus | ESCC | 1.20e-10 | 2.26e-01 | 0.1055 |
8491 | MAP4K3 | P28T-E | Human | Esophagus | ESCC | 8.65e-08 | 2.02e-01 | 0.1149 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
GO:00346129 | Cervix | CC | response to tumor necrosis factor | 55/2311 | 253/18723 | 1.75e-05 | 3.32e-04 | 55 |
GO:00093149 | Cervix | CC | response to radiation | 86/2311 | 456/18723 | 3.50e-05 | 5.63e-04 | 86 |
GO:00094112 | Cervix | CC | response to UV | 33/2311 | 149/18723 | 5.51e-04 | 5.29e-03 | 33 |
GO:00072545 | Cervix | CC | JNK cascade | 35/2311 | 167/18723 | 1.10e-03 | 9.09e-03 | 35 |
GO:00094163 | Cervix | CC | response to light stimulus | 54/2311 | 320/18723 | 1.03e-02 | 4.97e-02 | 54 |
GO:00514039 | Endometrium | AEH | stress-activated MAPK cascade | 50/2100 | 239/18723 | 9.33e-06 | 2.18e-04 | 50 |
GO:00310989 | Endometrium | AEH | stress-activated protein kinase signaling cascade | 51/2100 | 247/18723 | 1.12e-05 | 2.52e-04 | 51 |
GO:003461210 | Endometrium | AEH | response to tumor necrosis factor | 44/2100 | 253/18723 | 2.08e-03 | 1.61e-02 | 44 |
GO:000931410 | Endometrium | AEH | response to radiation | 70/2100 | 456/18723 | 3.99e-03 | 2.68e-02 | 70 |
GO:00072546 | Endometrium | AEH | JNK cascade | 30/2100 | 167/18723 | 6.16e-03 | 3.70e-02 | 30 |
GO:005140314 | Endometrium | EEC | stress-activated MAPK cascade | 55/2168 | 239/18723 | 3.98e-07 | 1.56e-05 | 55 |
GO:003109814 | Endometrium | EEC | stress-activated protein kinase signaling cascade | 56/2168 | 247/18723 | 5.25e-07 | 2.00e-05 | 56 |
GO:003461215 | Endometrium | EEC | response to tumor necrosis factor | 48/2168 | 253/18723 | 3.77e-04 | 4.03e-03 | 48 |
GO:000725414 | Endometrium | EEC | JNK cascade | 33/2168 | 167/18723 | 1.44e-03 | 1.17e-02 | 33 |
GO:000931413 | Endometrium | EEC | response to radiation | 71/2168 | 456/18723 | 5.69e-03 | 3.42e-02 | 71 |
GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
GO:003109818 | Esophagus | ESCC | stress-activated protein kinase signaling cascade | 154/8552 | 247/18723 | 8.53e-08 | 1.44e-06 | 154 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
hsa040108 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa0401011 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa0401021 | Lung | AIS | MAPK signaling pathway | 57/961 | 302/8465 | 6.41e-05 | 9.43e-04 | 6.03e-04 | 57 |
hsa0401031 | Lung | AIS | MAPK signaling pathway | 57/961 | 302/8465 | 6.41e-05 | 9.43e-04 | 6.03e-04 | 57 |
hsa0401010 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
hsa0401013 | Prostate | BPH | MAPK signaling pathway | 87/1718 | 302/8465 | 2.05e-04 | 1.13e-03 | 6.98e-04 | 87 |
hsa0401022 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
hsa0401032 | Prostate | Tumor | MAPK signaling pathway | 87/1791 | 302/8465 | 8.46e-04 | 3.94e-03 | 2.45e-03 | 87 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP4K3 | SNV | Missense_Mutation | c.602N>T | p.Gly201Val | p.G201V | Q8IVH8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
MAP4K3 | insertion | In_Frame_Ins | novel | c.763_764insAACTAGGCC | p.Thr255delinsLysLeuGlyPro | p.T255delinsKLGP | Q8IVH8 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
MAP4K3 | deletion | Frame_Shift_Del | novel | c.2366delT | p.Val789AspfsTer7 | p.V789Dfs*7 | Q8IVH8 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
MAP4K3 | SNV | Missense_Mutation | novel | c.1927C>T | p.Pro643Ser | p.P643S | Q8IVH8 | protein_coding | tolerated(0.36) | possibly_damaging(0.542) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP4K3 | SNV | Missense_Mutation | c.1957N>A | p.Asp653Asn | p.D653N | Q8IVH8 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
MAP4K3 | SNV | Missense_Mutation | novel | c.916G>C | p.Glu306Gln | p.E306Q | Q8IVH8 | protein_coding | deleterious(0.03) | benign(0.044) | TCGA-C5-A1BL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4K3 | SNV | Missense_Mutation | novel | c.2570N>C | p.Arg857Thr | p.R857T | Q8IVH8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EK-A2PK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4K3 | SNV | Missense_Mutation | novel | c.720N>A | p.Met240Ile | p.M240I | Q8IVH8 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
MAP4K3 | SNV | Missense_Mutation | novel | c.2107N>A | p.Glu703Lys | p.E703K | Q8IVH8 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4K3 | SNV | Missense_Mutation | c.80N>G | p.Tyr27Cys | p.Y27C | Q8IVH8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8491 | MAP4K3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 384403668 | ||
8491 | MAP4K3 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | inhibitor | 249565855 |
Page: 1 |